Micromedex vs Residipok

The Micromedex suite is a current, reliable, and robust solution to support informed clinical decisions with fast access to the latest evidence-based insights at the point of care. The impartial clinical content is updated daily and vetted through an accredited review process. The Micromedex app provides Drug Reference summary, NeoFax and Pediatric reference, IV Compatibility, and Drug Interactions information along with a set of clinical calculators and access to the Micromedex Assistant. What you will experience: – Unified Access: Access to all essential drug information from a single, comprehensive app – Ease of Navigation: User-friendly interface for easy access to information – Ease of Maintenance: Experience automated content updates so you can stay focused on your workflow App Activation Instructions: To successfully activate, your device needs to remain online. For quick and efficient downloading, remain within your facility Wi-Fi network. 1. Download the “Micromedex” app. The app will download to your app library or directly to your device. 2. Open the app, an activation code and an activation link will display on your device. a. Follow the link from your app. Enter your Micromedex login credentials, if required. OR b. Enter www.micromedexsolutions.com/activate in your desktop browser c. In your Micromedex desktop application, navigate to the Mobile Application Access tab and open the Mobile app access instructions and follow the provided link to the activation page. 3. Enter the provided activation code and tap “Activate Device” to begin using the app.

Residipok is a pocket reference for licensed healthcare professionals, trainees, and medical students of accredited health-professions programs. TWO MODULES (v0.4) • MIC Lookup Choose a bacterium and an antibiotic to see the EUCAST v16.0 (2026) Clinical Breakpoint thresholds — S, I, R bands by clinical context (systemic, meningitis, urinary, high-dose). Enter an MIC value to categorise it. Special states clearly labelled when no breakpoint is published or the organism is intrinsically resistant. Built especially for pan-resistance scenarios where every threshold matters. • ESC Guideline Reference Structured Class / Level of Evidence summaries of recent ESC cardiology guidelines, covering acute coronary syndromes, heart failure, atrial fibrillation, hypertension, endocarditis, cardiomyopathies, valvular disease, pulmonary hypertension and embolism, peripheral arterial disease, dyslipidaemia, prevention, pregnancy, syncope, supraventricular tachycardia, and more. Each recommendation card links back to the original guideline on escardio.org. IMPORTANT — REFERENCE ONLY • Residipok is NOT a medical device. • It does NOT diagnose, treat, cure, or prevent disease. • It is NOT a substitute for clinical judgement or for the original published guideline / breakpoint table. • Always verify against the current EUCAST table and the latest ESC document before clinical reporting. Requires confirmation of HCP / trainee status on first launch. Sign-in by email, Apple, or Google. Sources: EUCAST Clinical Breakpoint Tables v16.0 (2026); European Society of Cardiology Clinical Practice Guidelines (2018–2024).